Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

In sickle cell, start hydroxyurea in infancy

Schuchard S et al. ASPHO 2018, poster # 342 Schuchard S et al. ASPHO 2018, poster # 342. https://onlinelibrary.wiley.com/doi/10.1002/pbc.27057

Key clinical point: Early initiation of hydroxyurea is associated with better sickle cell disease outcomes.
Major finding: Patients started on hydroxyurea at a mean of 7.2 months had significantly fewer admissions, pain crises, and transfusions that patients started after age 1.
Study details: Retrospective review of data on 65 children with SCD in a single center.
Disclosures: The study was internally funded. Dr. Schuchard reported having no conflicts of interest.
Source: Schuchard S et al. ASPHO 2018, poster # 342. Schuchard S et al. ASPHO 2018, poster # 342. https://onlinelibrary.wiley.com/doi/10.1002/pbc.27057

Citation:

Schuchard S et al. ASPHO 2018, poster # 342. Schuchard S et al. ASPHO 2018, poster # 342. https://onlinelibrary.wiley.com/doi/10.1002/pbc.27057

This Week's Must Reads

Gene sequencing sheds light on outcomes in MPN, Grinfeld J et al. N Engl J Med. 2018;379:1416-30

Obesity lowers risk of death in PE patients, Khan Z et al. CHEST. 2018 Oct. doi: 10.1016/j.chest.2018.08.919

T cell infusion effective in PML, Muftuoglu M et al. N Engl J Med. 2018 Oct 11;379:1443-51

Post hoc analysis of SUSTAIN shows efficacy of crizanlizumab, Kutlar A et al. Am J Hematol. 2018 Oct 8. doi: 10.1002/ajh.25308

Must Reads in Bleeding Disorders

Laced synthetic cannabinoid leads to bleeding, Kelkar AH et al. N Engl J Med. 2018;379:1216-23.

Phase 3 data on emicizumab, Mahlangu et al. N Engl J Med. 2018;379:811-22

Integrated programs ease sickle cell pain, hospitalizations, Annual meeting of the Foundation for Sickle Cell Disease Research

Watch for RBC adhesion in men with sickle cell , Annual meeting of the Foundation for Sickle Cell Disease Research

FDA approves Jivi for hemophilia A, Package insert, news release